Abivax Reports Q1 2026 Financials and Key Developments in Obefazimod Trials

Abivax SA announced its Q1 2026 financial results, reporting significant progress in its trials for obefazimod, a drug aimed at treating ulcerative colitis (UC). The open-label extension trial, Study 108, showed that 68% of patients maintained remission after dose de-escalation from 50 mg to 25 mg over 144 weeks. No new safety signals were detected.

The company's financials indicate a cash position of €491.6 million, providing an operating runway into Q4 2027. R&D expenses rose to €49.5 million, driven by further developments and new indications for obefazimod. General and administrative costs decreased slightly due to reduced personnel expenses.

Upcoming milestones include results from the Abivax Phase 3 maintenance trial and further analysis of their Phase 2b trials for Crohn's disease. The company plans a NDA submission for obefazimod in UC by Q4 2026, contingent on positive outcomes.